BioCryst Pharmaceuticals | BCRX - Operating Expenses


BioCryst Pharmaceuticals reported $146.17M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
BioCryst Pharmaceuticals USD 146.17M 534.06M Dec/2025
Chugai Pharma JPY 162.98B 14.31B Mar/2026
Daiichi Sankyo JPY 468.57B 15.34B Dec/2025
DBV Technologies USD 37.05M 4.06M Sep/2025
Enanta Pharmaceuticals USD 126.59M 346.51M Dec/2025
Gilead Sciences USD 4.96B 707M Dec/2025
GlaxoSmithKline GBP 5.34B 1.85B Mar/2026
Glaxosmithkline GBP 9.17B 1.4B Dec/2025
Incyte USD 5.62B 4.5B Mar/2026
Ionis Pharmaceuticals USD 364M 54M Mar/2026
Karyopharm Therapeutics USD 51.92M 9.9M Dec/2025
Neurocrine Biosciences USD 577.6M 22M Dec/2025
Novavax USD 126.2M 23.62M Dec/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Roche Holding CHF 21.01B 10.84B Dec/2025
Sarepta Therapeutics USD 853.02M 390.78M Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026